Cargando…

Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology

Rilpivirine is an antiretroviral drug used to treat AIDS worldwide. The drug is a non-nucleoside reverse transcriptase inhibitor that halts the cDNA elongation process and, thus, the capacity of the HIV-1 virus to replicate. With the new wave of drug repurposing in recent years, rilpivirine has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Mariana, Vale, Nuno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917964/ https://www.ncbi.nlm.nih.gov/pubmed/36769210 http://dx.doi.org/10.3390/ijms24032890

Ejemplares similares

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2014)

The Role of Dopamine in Repurposing Drugs for Oncology
por: Moura, Catarina, et al.
Publicado: (2023)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Two Possible Strategies for Drug Modification of Gemcitabine and Future Contributions to Personalized Medicine
por: Pereira, Mariana, et al.
Publicado: (2022)

Evaluation of synergism in drug combinations and reference models for future orientations in oncology
por: Duarte, Diana, et al.
Publicado: (2022)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants
por: Smith, Steven J., et al.
Publicado: (2016)

Biochemical mechanism of clinical resistance to rilpivirine
por: Singh, Kamalendra, et al.
Publicado: (2012)

The development of an effective synthetic route of rilpivirine
por: Zhang, Tao, et al.
Publicado: (2021)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Entecavir: A Review and Considerations for Its Application in Oncology
por: Lourenço, Tânia, et al.
Publicado: (2023)

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
por: Moreno, Santiago, et al.
Publicado: (2023)

Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
por: Ford, Nathan, et al.
Publicado: (2011)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen, Opass, et al.
Publicado: (2013)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Understanding the Clinical Use of Levosimendan and Perspectives on its Future in Oncology
por: Ribeiro, Eduarda, et al.
Publicado: (2023)

Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
por: Vale, Nuno, et al.
Publicado: (2022)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa
por: Penrose, Kerri J, et al.
Publicado: (2018)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Observational cohort study of rilpivirine (RPV) utilization in Europe
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2022)

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1
por: Lombaard, Johan, et al.
Publicado: (2022)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
por: Zhang, Chun, et al.
Publicado: (2023)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less
por: Lucantoni, Federico, et al.
Publicado: (2022)

Novel drug delivery approaches on antiviral and antiretroviral agents
por: Sharma, Pooja, et al.
Publicado: (2012)

Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug
por: Ameen, Fuad, et al.
Publicado: (2021)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy
por: Moffatt, Kurtis, et al.
Publicado: (2022)

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance
por: Charpentier, Charlotte, et al.
Publicado: (2023)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Understanding Lamotrigine’s Role in the CNS and Possible Future Evolution
por: Costa, Bárbara, et al.
Publicado: (2023)

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lf8vfb7c2u8l17uu1edn5gc1v6